The Federal Trade Commission has paused its case against CVS Caremark to review a proposed consent agreement that would resolve all claims against the company. The March 23 joint motion from the FTC complaint counsel and CVS Caremark asks the…
Pharmacy
The FDA’s Office of Prescription Drug Promotion has issued a warning letter to drugmaker ImmunityBio over misleading promotional materials for Anktiva, a bladder cancer drug. The March 13 letter cited a TV advertisement and a podcast featuring Richard Adcock, president…
HHS has awarded $8.3 million to the API Innovation Center to expand domestic manufacturing of two essential hospital medicines: metoprolol and propofol. The funding will support end-to-end U.S. production of metoprolol for the first time in decades, according to a…
The ongoing shortage of ADHD medications in the U.S. may be driven by international supply chain disruptions, adding a new dimension to concerns that have largely focused on rising demand and federal production limits. Researchers from New Haven, Conn.-based Yale…
The House Select Committee on China warned that the U.S. is increasingly dependent on China for both the raw materials used in generic drugs and the development of new therapies. Roughly 90% of all U.S. prescriptions are generics, and 83…
Advertisement
Drug Channels Institute has released its annual pharmacy and PBM market outlook, detailing how retail dynamics, payer influence and vertical integration are shaping the $500 billion U.S. prescription drug ecosystem. Here are five key trends from the “2026 Economic Report…
Detroit-based Barbara Ann Karmanos Cancer Institute has become the first independent cancer center in the U.S. to provide a one-time gene therapy for the treatment of hemophilia B in adults. The first patient received the therapy — called Hemgenix —…
Pfizer and Valneva’s investigational Lyme disease vaccine candidate, PF-07307405 (LB6V), demonstrated more than 70% efficacy in preventing Lyme disease among individuals age 5 and older, according to topline phase 3 trial results. The prespecified analysis showed 74.8% efficacy starting one…
Bristol Myers Squibb has received two expanded U.S. approvals for Opdivo (nivolumab) combinations that establish additional immunotherapy options for classical Hodgkin lymphoma across pediatric and adult populations. The FDA approved Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) for…
The Institute for Safe Medication Practices outlined 15 strategies for reducing medication errors in clinical settings in its 2026-2027 “Targeted Medication Safety Best Practices for Hospitals.” The update includes three new best practices and 12 carried forward from previous cycles.…